ENO1

Across TCGA pan-cancer cohorts, ENO1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ENO1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ENO1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENO1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ENO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.262	0.559	.006	32	view →
LSCC	OS	Median	All	1.000	0.936	.009	18	view →
LUAD	OS	Median	II,III,IV	0.395	0.816	.003	17	view →
UCEC	OS	Median	II,III,IV	1.000	0.638	.014	6	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	2	view →
GBM	DFS	Median	All	0.651	0.782	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ENO1–PDAC (DFS)

Open the PDAC breakdown →